Will I need it done again?

The numbers, side by side

A systematic review and meta-analysis of 119 studies and 130,106 patients reported reoperation rates for ten different procedures at one, two, three and five years.¹ At five years:

| Procedure | Reoperation at 5 years | |---|---| | Aquablation | 4.1% | | Open prostatectomy | 4.4% | | Plasma-kinetic resection | 6.6% | | HoLEP | 6.6% | | Photoselective vaporisation | 7.1% | | TURP | 7.7% | | Thulium enucleation | 8.4% | | Bladder-neck incision | 13.4% | | Prostate artery embolisation | 23.8% | | Microwave thermotherapy | 31.2% |

Two things stand out. The gap between the established resection and enucleation operations is small — TURP and HoLEP are within a percentage point of each other at five years. And the gap between those and embolisation or microwave therapy is very large indeed.

Why HoLEP's reputation for durability is about the long run

At five years HoLEP and TURP look similar. They diverge later, and the reason is mechanical: enucleation removes the adenoma down to the surgical capsule, so there is less tissue left to regrow.

The randomised trial with the longest follow-up compared HoLEP with TURP at a mean of 7.6 years and found HoLEP at least equivalent, with fewer re-operations — none in the HoLEP arm against three of seventeen assessable men after TURP.² A three-year analysis of over 33,000 primary procedures found HoLEP significantly reduced reoperation risk compared with TURP.³ And in a systematic review of studies with at least five years' follow-up, HoLEP's mean reoperation rate was 4.1% at a mean 7.3 years, against 12.6% for GreenLight vaporisation.⁴

So the honest statement is not "HoLEP lasts and TURP does not". It is that the durability advantage is real but appears beyond five years, and is largest against vaporising rather than resecting techniques.

The newer devices, honestly

For the minimally invasive treatments the picture is genuinely mixed, and the short-term data flatter them.

A network meta-analysis of re-intervention rates for UroLift, Aquablation, Rezūm, embolisation and iTIND found rates at twelve months comparable to TURP, with some procedures better in the short term.⁵ Twelve months is not the horizon that matters. The same review notes that clinical durability for these interventions "is not widely known".

Aquablation has the best longer-run data of the group: the WATER and WATER II five-year update found 95% and 97% of men free from surgical retreatment across small and large prostates respectively.⁶ That is a strong result and it is why Aquablation sits at the top of the five-year table above.

Real-world data are less flattering than trials. A nationwide analysis using a large US health-record network found the minimally invasive treatments had higher rates of retreatment and medication restart than the traditional operations.⁷ Trial populations are selected; the men in your waiting room are not.

What "needing it again" actually means

It is not necessarily another operation. Retreatment in these studies includes going back onto medication, which many men would regard as a lesser failure than a second anaesthetic.

It is worth asking which is being counted. A quoted "4% retreatment" that excludes medication restart is not comparable with one that includes it.

Does a first operation make the second harder?

This is the question I would ask if I were choosing a minimally invasive option first, and it deserves a specific answer rather than a reassuring one.

Implants placed in the urethra have to be dealt with at any subsequent operation. Tissue that has been ablated by heat or steam is not identical to untouched tissue at enucleation. A European perspective comparing Aquablation with enucleation concluded that enucleation provides superior long-term durability while Aquablation offers better functional preservation and a shorter learning curve — a fair summary of the trade, and one that assumes the choice is made deliberately rather than by default.⁸

The general position is that sequential procedures are common and usually manageable. But "we can always do a TURP later" should come with an account of what the first procedure leaves behind.

What to ask

1. What is your five-year retreatment rate for this procedure — and does that number include restarting tablets?
2. Given my prostate volume, am I at the favourable or unfavourable end of that figure?
3. If this needs redoing, what is the second operation, and does the first make it harder?
4. Would you make the same recommendation if I told you I never wanted to do this twice?

Bottom line

If durability is what you are buying, enucleation and resection are the evidence-backed choices, with the advantage widening after five years. Aquablation now has genuinely competitive five-year retreatment data. Embolisation and microwave therapy do not, and men should know that before choosing them for the gentler recovery.

The gentler the operation, generally, the greater the chance of doing it again. That is the trade — and it is a legitimate one to accept, as long as it is stated.

Worth reading alongside: which operation should I have?, and the Evidence Notes on each procedure.